Dr. Francisco Dasí Fernández

Principal Investigator
Research Group on Rare Respiratory Diseases (RRD)

Presentation

Dr. Francisco Dasí Fernández. Degree in Biology and PhD in Pharmacology from the Universitat de València with outstanding cum laude qualification unanimously. In 2007, he joined the Miguel Servet program of the Instituto de Salud Carlos III (ISCIII) to develop his research work at the Fundación para la Investigación del Hospital Clínico Universitario de València-Instituto de Investigación Sanitaria INCLIVA. In 2013, the ISCIII rated his research work as positive, and, at present, he is a researcher within the IIS INCLIVA, where he leads the Group of Respiratory Rare Diseases. He is an associate professor of the Department of Physiology of the Faculty of Medicine of the University of Valencia.

He has supervised 10 doctoral theses, all of them with the qualification of outstanding cum laude and 15 Master and Degree Final Projects. His line of research focuses on the study of the pathophysiology of alpha-1 antitrypsin deficiency and primary ciliary dyskinesia syndrome, more specifically, in the search for diagnostic and prognostic biomarkers, as well as advanced techniques for the correction of the genes involved in these pathologies (gene therapy and CRISPR/Cas9). He has published 62 articles in indexed journals. He has participated as a speaker in 87 national and international congresses. He is the author of 5 chapters of research, teaching, and informative books, two of which are guides for patients and relatives with alpha-1 antitrypsin deficiency. He has participated as principal investigator (10) and as a collaborating investigator (20) in 30 research projects funded by the national plan (ISCIII and SAF), the Autonomous Community of Valencia, and various Medical Societies. He has participated in the organizing committee of 7 national and international congresses. He has made three research stays in centers of international prestige, of which he maintains collaboration with the Karolinska Institutet, in Stockholm, Sweden, and the Lineberger Cancer Center in North Carolina, USA. He has obtained a total of 13 grants (6 predoctoral and 7 postdoctoral). For his research work, he has received 5 research awards.

Currently, and since 2012, he is the coordinator of the transversal line of Rare Diseases of INCLIVA and scientific advisor of the patient’s association Alfa-1 Spain, of the National Registry of Patients with alpha-1 antitrypsin deficiency (REDAAT) and the Lovexair Foundation. Since 2013, he has been a member of the Research Ethics Committee of the Hospital Clínico de Valencia, scientific advisor of the Scientific Culture and Innovation Unit of the Universitat de València, and coordinator of the working group on Rare Diseases of the Vice-Rectorate of Culture of the University of Valencia. He is an editor in several international scientific journals and an evaluator of the National Agency for Quality Assessment and Accreditation-ANECA. In 2015, he joined the European research group on Primary Ciliary Dyskinesia (eCOST BEAT-PCD as an alternate Spanish representative).

Principal
Investigator

francisco.dasi@uv.es